CADL stock icon

Candel Therapeutics
CADL

$6.04
1.51%
 

About: Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Employees: 42

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

1% more capital invested

Capital invested by funds: $5.92M [Q4 2023] → $5.97M (+$53K) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0.85% less ownership

Funds ownership: 13.93% [Q4 2023] → 13.07% (-0.85%) [Q1 2024]

9% less funds holding

Funds holding: 22 [Q4 2023] → 20 (-2) [Q1 2024]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Research analyst outlook

We haven’t received any recent analyst ratings for CADL.

Financial journalist opinion

Based on 4 articles about CADL published over the past 30 days